Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BBO-8520 + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- BridgeBio Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
BBO-8520 + pembrolizumab is a combination therapy consisting of BBO-8520, a first-in-class direct and covalent dual inhibitor of KRAS G12C (ON and OFF forms), and pembrolizumab, an anti-PD-1 monoclonal antibody. BBO-8520 binds in the Switch-II/Helix3 pocket of KRAS G12C, covalently modifies the target cysteine, and disables effector binding to both active and inactive forms of KRAS G12C, providing optimal target coverage. This combination aims to simultaneously target cancer cells directly through KRAS inhibition while activating the immune system against the tumor.
- Other names
- BBO-8520 + KeytrudaBBO-8520 + MK-3475BBO-8520 + pembrolizumabKeytruda + BBO-8520MK-3475 + BBO-8520pembrolizumab + BBO-8520
02
Targets
KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BBO-8520 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BBO-8520 + pembrolizumab.